Skip to main content

05 NOVEMBER, 2004

bioMérieux reveals VIDIA, its new automated immunoanalyser, in Paris at the Journées Internationales de Biologie

Marcy l'Etoile, France - November 5th, 2004. A major player in the in vitro diagnostics marketplace, bioMérieux announces the first official presentation of its new fully automated immunoanalyser, VIDIA®. The system will be presented to healthcare professionals at the Journées Internationales de Biologie held in Paris from November 4 - 6, 2004.

With over 30 years of experience in the field of immunoassays, bioMérieux has developed the VIDIA system in response to clinical laboratory expectations in terms of automation, traceability and ease-of-use. The system design also integrates the high level of expertise which has positioned the VIDAS system, launched thirteen years ago by bioMérieux, as a reference in immunoanalysis. Over 18,000 VIDAS and miniVIDAS are installed worldwide, making bioMérieux a leader in the immunoassay field.

« With VIDIA, bioMérieux extends its global immunoassay offer and meets the requirements of today’s clinical laboratories » states Christian Melis, Business Area Manager for Immunoassays at bioMérieux.

VIDIA, which has an hourly throughput rate of 80 to 110 tests, is intended for use by clinical laboratories for routine testing, and by laboratories specializing in the diagnosis of infectious diseases.

VIDIA will provide an extensive reagent menu, covering the fields of infectious diseases (toxoplasmosis, rubella, cytomegalovirus, HIV, hepatitis, Epstein Barr virus, syphilis, varicella, Lyme disease) as well as hormonology (thyroid function, fertility), cancer (tumor markers) and the diagnosis of anemia.

The fully automated VIDIA system offers the flexibility of working with primary tubes, and uses chemi-luminescent analytics. The software, with its extremely user-friendly graphical interface, ensures secure system and result management. VIDIA provides the clinical laboratory with fully automated traceability of each result, both from the test itself and from the calibration and controls.

Furthermore, with VIDIA® and VIDAS®, bioMérieuxs offer a global solution adapted to laboratory requirements, with VIDIA processing 80% of the laboratory’s test volume and VIDAS® as the ideal system for emergency, specific or low-volume tests. Together, the two systems provide a wide menu of over 100 different immunoassays, covering more that 10 panels. In addition, the laboratory benefits from complete agreement between VIDIA and VIDAS results, which is particularly useful for comparing routine and back-up test results. A bi-directional connection interface, BCI Net™, provides an optimized data management link between the laboratory’s information system and up to 5 VIDAS and/or VIDIA systems.

« Based on the experience and know-how acquired through VIDAS, bioMérieux continues to innovate in the field of immunoanalysis with VIDIA, » adds Christian Melis.

The first VIDIA systems will be installed in 2005.

bioMérieux will provide clinical laboratories with over 130 different immunoassays through a complete offer of systems and reagents, ranging from rapid single-dose tests, VIKIA®, to the high-throughput fully automated microplate processor, DAVINCI® and to the fully automated multiparametric analysers, VIDAS, miniVIDAS and VIDIA.